Testosterone Replacement Therapy for Prostate Cancer

Not yet recruiting at 1 trial location
TM
LA
Overseen ByLaura Angulo Llanos
Age: 18+
Sex: Male
Trial Phase: Phase 4
Sponsor: University of Miami
Must be taking: Testosterone
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests the safety of testosterone replacement therapy in men with newly diagnosed low-risk prostate cancer who are monitored rather than treated aggressively (known as active surveillance) and have low testosterone levels. Participants will self-inject testosterone cypionate, a form of testosterone replacement therapy, weekly for a year. This trial suits men diagnosed with low-risk prostate cancer within the last year, who experience symptoms of low testosterone, and can access testosterone medication through insurance or out-of-pocket. As a Phase 4 trial, this research aims to understand how this FDA-approved and effective treatment benefits more patients.

Do I need to stop taking my current medications for the trial?

The trial information does not specify if you need to stop taking your current medications. However, it does exclude those currently using testosterone replacement therapy.

What is the safety track record for testosterone cypionate?

Research shows that testosterone replacement therapy (TRT) is generally safe for men. Studies have found that TRT does not significantly increase the risk of prostate cancer recurrence or progression after initial treatment. One study found prostate cancer in 0.5% of men using testosterone, compared to 0.4% of those not using it, indicating a very small difference.

Testosterone therapy has been linked to a slightly higher risk of benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate. However, evidence suggests that TRT does not significantly increase the risk of developing new prostate cancer.

Overall, TRT has been used safely in men, even those with a history of prostate cancer, without major concerns. This study aims to further explore its safety in men with low-risk prostate cancer and low testosterone levels (hypogonadism).12345

Why are researchers enthusiastic about this study treatment?

Testosterone cypionate is unique because it challenges the traditional approach to prostate cancer treatment. Most treatments for prostate cancer focus on reducing testosterone levels, as the hormone can fuel cancer growth. However, testosterone cypionate takes a different route by actually adding testosterone, aiming to disrupt cancer cells' ability to adapt and survive without the hormone. Researchers are excited about this treatment because it could potentially reverse the cancer's growth or make it more susceptible to other therapies, offering a new hope for patients who have limited options.

What evidence suggests that testosterone replacement therapy might be an effective treatment for low-risk prostate cancer?

Research has shown that testosterone replacement therapy (TRT) can be safe for men with prostate cancer. In this trial, participants will receive testosterone cypionate, a form of TRT. Studies have found that men using TRT are 54% less likely to experience a recurrence of prostate cancer. Another study discovered that TRT does not significantly raise prostate-specific antigen (PSA) levels, which doctors often monitor in prostate cancer patients. Additionally, TRT has been linked to a 15% lower long-term risk of developing prostate cancer. Overall, testosterone cypionate appears to improve quality of life without increasing the risk of prostate cancer progression.23678

Who Is on the Research Team?

TM

Thomas Masterson, MD

Principal Investigator

University of Miami

Are You a Good Fit for This Trial?

This trial is for men with low-risk prostate cancer who are being closely monitored (active surveillance) and also have hypogonadism, a condition where the body doesn't produce enough testosterone. Specific eligibility details aren't provided.

Inclusion Criteria

Willing and able to provide written informed consent and able to comply with study requirements
I am a man aged 18 or older.
I was recently diagnosed with low-risk prostate cancer confirmed by two biopsies.
See 4 more

Exclusion Criteria

Any other condition or situation which, in the opinion of the investigator, could impact patient safety, prevent successful data collection, or reduce the likelihood of successful study participation
Unable or unwilling to provide informed consent or comply with study requirements
I cannot or do not want to get Testosterone through insurance or by paying myself.
See 9 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants self-inject 100mg of testosterone cypionate once per week

12 months
Weekly self-injections

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 months
Regular assessments at baseline and 12 months

Long-term follow-up

Participants are monitored for progression-free survival

5 years

What Are the Treatments Tested in This Trial?

Interventions

  • Testosterone cypionate

Trial Overview

The study is testing the safety of giving testosterone cypionate, a hormone replacement therapy, to men with low-risk prostate cancer and hypogonadism to see if it's safe and doesn't worsen their cancer.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Testosterone cypionateExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Miami

Lead Sponsor

Trials
976
Recruited
423,000+

Citations

The Effect of Testosterone Replacement Therapy on ...

The results of this study indicate that testosterone replacement therapy does not increase PSA levels in men being treated for hypogonadism, except when it is ...

Association Between Testosterone Replacement Therapy and ...

Similarly, long-term TRT use demonstrated a similar 15% reduced hazard of PCa and a 13% increased hazard of BPH. These results align with previous study ...

Testosterone Therapy for Patients with a History of Prostate ...

Patients on TTh were almost 54% less likely to have a prostate cancer recurrence. In men expected to have a prostate specific antigen (PSA) ...

Testosterone therapy and prostate cancer - Pastuszak

TTh results in improvements in quality of life with little evidence of biochemical recurrence or progression in men with a history of CaP, or de novo cancer in ...

Cardiovascular Safety of Testosterone-Replacement Therapy

Prostate cancer occurred in 12 patients (0.5%) in the testosterone group and in 11 patients (0.4%) in the placebo group (P=0.87); these cases were adjudicated ...

Testosterone Replacement Therapy and Prostate Cancer ...

Investigators have reported favorable outcomes with testosterone supplementation after radical prostatectomy.

SUO 2024: Testosterone Supplementation After Treatment ...

Early data has not demonstrated any increased risk of prostate cancer recurrence or progression in men using TRT after prostate cancer ...

Testosterone Replacement Therapy in Hypogonadal ...

The purpose of this study is evaluate the safety of testosterone replacement therapy in men with newly diagnosed low-risk prostate cancer and ...